Effectiveness and Safety of Glycoprotein IIb/IIIa Inhibitors and Clopidogrel Alone and in Combination in Non-ST-Segment Elevation Myocardial Infarction (from the National Registry of Myocardial Infarction-4)

American Journal of Cardiology

Volumn 98, Issue 9, 2006, Pages 1125-1131

  Bromberg Marin, Guilherme ^a   Marin Neto, Jose A ^b   Parsons, Lori S ^c   Canto, John G ^d   Rogers, William J ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Ovation Research Group   (United States)

^d Watson Clinic   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; CONFIDENCE INTERVAL; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; TIME SERIES ANALYSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HEART CONDUCTION SYSTEM; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; REGISTRIES; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 33750181384     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.05.043     Document Type: Article

References (23)

1. Rogers W.J., Bowlby L.J., Chandra N.C., French W.J., Gore J.M., Lambrew C.T., Rubison R.M., Tiefenbrunn A.J., and Weaver W.D. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation 90 (1994) 2103-2114
2. Canto J.G., Rogers W.J., Bowlby L.J., French W.J., Pearce D.J., and Weaver W.D. The pre-hospital electrocardiogram in acute myocardial infarction: is its full potential being reached?. J Am Coll Cardiol 29 (1997) 498-505
3. Every N.R., Frederick P.D., Robinson M., Sugarman J., Bowlby L., and Barron H.V. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol 33 (1999) 1886-1894
4. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., Jones R.H., Kereiakes D., Kupersmith J., Levin T.N., et al., American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002) 1893-1900
5. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO IV-ACS randomized trial. Lancet 357 (2001) 1915-1924
6. The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
7. Mehta S.R., Yusuf S., Peters R.J.G., Bertrand M.E., Lewis B.S., Natarajan M.K., Malmberg K., Rupprecht H., Zhao F., Chrolavicius S., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
8. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339 (1998) 436-443
9. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave acute myocardial infarction. N Engl J Med 338 (1998) 1488-1497
10. Peterson E.D., Pollack Jr. C.V., Roe M.T., Parsons L.S., Littrell K.A., Canto J.G., Barron H.V., and National Registry of Myocardial Infarction (NRMI) 4 Investigators. Early use of glycoprotein IIb/IIIa inhibitors and outcomes in non-ST elevation MI: observations from the NRMI-4. J Am Coll Cardiol 42 (2003) 45-53
11. Boersma E., Harrington R.A., Moliterno D.J., White H., Théroux P., Van de Werf F., de Torbal A., Armstrong P.W., Wallentin L.C., Wilcox R.G., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359 (2002) 189-198
12. EPIC Investigators. Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330 (1994) 956-961
13. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349 (1997) 1429-1435
14. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
15. Kleiman N.S., Lincoff A.M., Flakeret G.C., Pieper K.S., Wilcox R.G., Berdan L.G., Lorenz T.J., Cokkinos D.V., Simoons M.L., Boersma E., et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 101 (2000) 751-757
16. EPISTENT Investigators. Randomised placebo-controlled and balloon angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 352 (1998) 87-92
17. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 356 (2000) 2037-2044
18. Topol E., Moliterno D., Herrmann H., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., et al., TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischaemic events with percutaneous coronary revascularization. N Engl J Med 344 (2001) 1888-1894
19. Kastrati A., Mehilli J., Schühlen H., Dirschinger J., Dotzer F., ten Berg J.M., Neumann F.J., Bollwein H., Volmer C., Gawaz M., et al., Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350 (2004) 232-238
20. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., Topol E.J., and CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
21. Kastrati A., Mehilli J., Neumann F.J., Dotzer F., ten Berg J., Bollwein H., Graf I., Ibrahim M., Pache J., Seyfarth M., et al., Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295 (2006) 1531-1538
22. Steinhubl S., Ellis S.G., Wolski K., Lincoff A.M., and Topol E.J. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 103 (2001) 1403-1409
23. Chan A.W., Moliterno D.J., Berger P.B., Stone G.W., DiBattiste P.M., Yakubov S.L., Sapp S.K., Wolski K., Bhatt D.L., Topol E.J., and TARGET Investigators. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195